Abstract 56P
Background
Chimeric antigen receptor (CAR) and bispecific T-cell engagers (BiTEs) targeting CD19 had impressive antitumor efficacy for relapsed/refractory acute lymphoblastic leukemia but are limited responses for aggressive B-cell lymphoma (BCL). Programmed death-ligand 1 (PD-L1) overexpression on a tumor cell is a significant obstacle to objective responses after CAR-T cell therapy. Since immune checkpoint inhibitors combined with CAR-T cells may not wholly eradicate resistant solid tumors, redirecting PD-L1 and CD3 expressing cells using PD-L1 x CD3e BiTE may improve CAR-T cell antitumor functions.
Methods
To mitigate PD-L1 mediated CAR-T cell suppression, we engineered anti-CD19-CAR-T cells to secrete PD-L1 x CD3 BiTE (PD-L1 BiTE). A 4-1BB-based second-generation CD19-CAR comprising FMC63 scFv was linked with PD-L1 scFv x CD3e scFv (CD19-CAR.PD-L1 BiTE) via a T2A. PD-L1+/HeLa-CD19+ cell was used as a model to investigate whether the exogenous supply with PD-L1 BiTE or secreted by CAR-T can facilitate the antitumor activity of CD19-CAR T-cells.
Results
The antitumor activity of CD19-CAR T-cells co-incubated with recombinant PD-L1 BiTE showed superior cytolytic activity to CD19-CAR T-cells or PD-L1 BiTE alone. Primary human T cells expressing CD19-CAR.PD-L1 BiTE can secrete PD-L1 BiTE into the culture medium and exert bioactivities on specific binding to PD-L1 and CD3. CD19-CAR.PD-L1 BiTE significantly enhanced antitumor function and cytokine production against Raji/PD-L1 tumor cells. Taken together, these results proved the concept that a combination of CD19-CAR T-cells with either recombinant PD-L1 BiTE or self-secreted CAR-T cells could effectively enhance antitumor efficacies against PD-L1+/CD19+ tumor cells.
Conclusions
We demonstrated that PD-L1 blockade concomitant with redirecting CD3+ T cells mediated by PD-L1 BiTE secreted from anti-CD19-CAR2-T cells can improve CAR-T antitumor efficiency against PD-L1-positive tumors. This finding highlighted that concomitantly secreted PD-L1xCD3 BiTEs by CAR T-cells is a promising strategy to overcome PD-L1-mediated immune cell suppression to achieve synergistic efficacy for solid tumor treatment.
Legal entity responsible for the study
The authors.
Funding
The National Science and Technology Development Agency (NSTDA) (grant no. P1650727).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
Resources:
Abstract
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
Resources:
Abstract
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
Resources:
Abstract
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
Resources:
Abstract
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
Resources:
Abstract
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
Resources:
Abstract
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
Resources:
Abstract
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session
Resources:
Abstract
133P - The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: A single-arm, open-label, multicenter phase II clinical trial
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract
134P - Intracranial (IC) progression-free survival (PFS) with ivonescimab (Ivo) compared to placebo in the HARMONi-A trial of patients (Pts) with previously treated EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC)
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract